Novo Nordisk’s Strategic Pivot: Can a Higher-Dose Wegovy Offset Alzheimer’s Setback?

Following a punishing week for its share price, Novo Nordisk has launched a strategic counteroffensive. The Danish pharmaceutical giant, still reeling from a significant clinical trial failure, is fighting back with a major regulatory move. The central question for investors is whether a new, higher-dose formulation of its weight-loss drug Wegovy can restore market confidence, or if this represents merely a temporary diversion from deeper challenges.

In a swift response to recent pressures, Novo Nordisk disclosed on Friday, November 28, that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration. The application seeks approval for a 7.2 mg dosage of Wegovy, a substantial increase from Read more...